特应性皮炎患者的治疗需求:一项真实世界队列研究
本研究基于TREATgermany注册队列,纳入697例中重度特应性皮炎成人患者,在基线和2年随访时使用患者获益指数评估治疗目标重要性和达成度。结果显示止痒是最优先目标,不同亚组需求存在差异,2年后96.6%报告有意义的治疗获益,患者报告结局与感知获益的关联强于医生评估指标。
要点
- 止痒是成人中重度特应性皮炎患者最常优先的治疗目标。
- 治疗需求因年龄、性别、教育程度和发病年龄而异。
- 患者报告结局比医生评估更贴合患者感知的治疗获益。
核心结论
- 特应性皮炎患者治疗需求因人口学和临床因素而异,瘙痒始终为最高优先级。
- 患者报告结局与感知获益的关联强于医生评估,系统需求评估有助于个体化治疗和共享决策。
研究设计与样本
- 前瞻性观察性研究,来自TREATgermany注册队列,纳入697例中重度特应性皮炎成人患者。
- 患者在基线(T1)和2年随访(T2)完成经验证的患者获益指数(PBI),评估治疗目标重要性和达成度。
- 按年龄、性别、教育程度和AD发病年龄进行亚组分析,并分析临床指标与感知获益的关联。
主要发现
- 最常优先的治疗目标为无瘙痒(97.8%高度同意)、重新控制疾病(95.3%)和缓解皮肤灼烧感(92.0%)。
- 瘙痒减轻的重要性与基线瘙痒强度不相关,感知获益与相对临床改善的关联比绝对疾病严重度更密切。
- 老年患者重视治疗安全性和减少医疗依赖,女性强调心理社会和外观相关目标,低教育程度者关注经济负担,成人发病患者优先考虑诊断确定性和疾病控制。
- 2年后96.6%的患者报告有意义的治疗获益,62%报告大幅获益。
- 患者报告结局(POEM)与感知获益的关联强于医生评估指标(oSCORAD、EASI)。
关键数值与推荐
- 无瘙痒:97.8%高度同意;重新控制疾病:95.3%;缓解皮肤灼烧感:92.0%。
- 2年后96.6%报告有意义的治疗获益,62%报告大幅获益。
临床怎么用
- 临床应主动询问患者的个体化治疗优先事项,而非假设统一目标。
- 理解每位患者最看重的需求可能改善治疗选择和照护满意度。
- 患者报告结局比医生评估更贴合患者感知获益,可辅助治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Atopic dermatitis (AD) substantially affects quality of life, yet standardized severity measures may not capture patient-centred priorities, making systematic needs assessment essential for personalized care. OBJECTIVES: This study aimed to systematically assess and rank treatment needs in adults with moderate to severe AD, identify patient subgroups with distinct need profiles and evaluate how well these needs were met after 2 years of specialized dermatological care. METHODS: In this prospective observational study from the TREATgermany registry, 697 adults with moderate to severe AD completed the validated Patient Benefit Index (PBI) at baseline (T1) and at 2-year follow-up (T2), capturing treatment goal importance and achievement. Subgroup analyses were performed based on age, sex, educational status and age at AD onset. Associations between clinical measures and perceived benefit were analysed. RESULTS: The most frequently prioritized treatment goals were being free of itching (97.8% high agreement), regaining control of the disease (95.3%) and relief from skin burning (92.0%). The importance of itch reduction was not correlated with baseline pruritus intensity, and perceived benefit was more closely linked to relative clinical improvement than to absolute disease severity. Beyond these shared priorities, treatment needs varied across subgroups: older patients valued treatment safety and reduced dependence on medical care, women emphasized psychosocial and appearance-related goals, individuals with lower educational status highlighted financial concerns and patients with adult-onset AD prioritized diagnostic certainty and disease control. After 2 years, 96.6% of patients reported meaningful treatment benefit. Patient-reported outcomes (POEM) were more strongly associated with perceived benefit than physician-assessed measures (oSCORAD, EASI). CONCLUSION: Patient treatment needs in AD vary by demographic and clinical factors, with pruritus consistently rated as the highest priority. Patient-reported outcomes align more closely with perceived benefit than physician assessments, underscoring the value of systematic needs assessments to guide individualized treatment decisions and shared decision-making. UNLABELLED: WHAT IS THE DISEASE?: Atopic dermatitis (eczema) is a common skin condition causing dry, itchy skin and recurring rashes, affecting 3%–7% of adults and 15%–25% of children, significantly impacting quality of life and emotional well‐being. LOCATION OF THE STUDY: This research was conducted in Germany using data from the TREATgermany registry, including patients from hospitals and dermatology practices nationwide. AIM OF THE STUDY: We aimed to understand which treatment goals matter most to adults with moderate to severe eczema, whether patient groups differ in their priorities and how well these needs are met after specialist care. METHODOLOGY: We studied 697 adults with moderate to severe eczema over 2 years. Patients completed questionnaires rating the importance of different treatment goals and how well these were achieved, with comparisons across age, sex, education and disease onset. KEY FINDINGS: Relief from itching was the top treatment priority (97.8% answered ‘quite’ or ‘very’ important). Different groups had distinct needs: Older patients valued treatment safety and fewer doctor visits, women emphasized appearance and emotional well‐being, patients with lower educational status worried about treatment costs and those with adult‐onset disease feared disease progression. After 2 years, 96.6% reported meaningful treatment benefit and 62% reported large benefit. Improvement in patients' own symptom ratings corresponded more closely with treatment satisfaction than improvement measured by doctors. CONCLUSIONS AND PRACTICAL IMPLICATIONS: Doctors should ask patients about their individual treatment priorities rather than assuming uniform goals. Understanding what matters most to each patient could improve treatment selection and satisfaction with care.
引用
- Ludemann K, Traidl S, Cornelius A, et al. Patient treatment needs in atopic dermatitis: A real-world cohort study. J Eur Acad Dermatol Venereol. 2026. PMID: 42530227. doi:10.1111/jdv.70648
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。